guest ::
| Home > Publications database > Vaccine Strategies in Gliomas. > print |
| Home > Publications database > Vaccine Strategies in Gliomas. > print |
| 001 | 132944 | ||
| 005 | 20240229105041.0 | ||
| 024 | 7 | _ | |a 10.1007/s11940-018-0498-1 |2 doi |
| 024 | 7 | _ | |a pmid:29594595 |2 pmid |
| 024 | 7 | _ | |a 1092-8480 |2 ISSN |
| 024 | 7 | _ | |a 1534-3138 |2 ISSN |
| 024 | 7 | _ | |a altmetric:35023365 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2018-00583 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Platten, Michael |0 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Vaccine Strategies in Gliomas. |
| 260 | _ | _ | |a Philadelphia, Pa. |c 2018 |b Current Science Inc. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1660118080_9237 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a To discuss the current state of glioma vaccine development and highlight the challenges associated with clinical implementation of these approaches.Vaccination strategies against gliomas have matured considerably during the past years, although proof-of efficacy from controlled clinical trials is still lacking. Advances in antigen discovery, including the definition of neoepitopes including epidermal growth factor receptor variant III (EGFRvIII), isocitrate dehydrogenase (IDH)1R132H and Histone (H)3.3K27M, using multi-omic approaches and computational algorithms allow targeting single antigens, but also implementing truly personalized approaches. In addition, new concepts of vaccine manufacturing including RNA and DNA vaccines improve immunogenicity and applicability in personalized settings. As an increasing amount of clinical data defy the concept of the central nervous system (CNS) as a strictly immunoprivileged site, novel vaccine approaches enter the clinic including critical efforts to identify biomarkers of response and resistance and strategies to overcome the immunosuppressive glioma microenvironment. |
| 536 | _ | _ | |a 317 - Translational cancer research (POF3-317) |0 G:(DE-HGF)POF3-317 |c POF3-317 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Bunse, Lukas |0 P:(DE-He78)e579130c57e8c686ed1c2dedfa595985 |b 1 |u dkfz |
| 700 | 1 | _ | |a Riehl, Dennis |0 P:(DE-He78)567e98aaf50a1f3be9ef2f365dda213d |b 2 |u dkfz |
| 700 | 1 | _ | |a Bunse, Theresa |0 P:(DE-He78)e681100c540b628a2bdbd48772b4fb50 |b 3 |u dkfz |
| 700 | 1 | _ | |a Ochs, Katharina |0 P:(DE-He78)0f9fbf5fd70dad2bba0760cee65c9613 |b 4 |u dkfz |
| 700 | 1 | _ | |a Wick, Wolfgang |0 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee |b 5 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1007/s11940-018-0498-1 |g Vol. 20, no. 5, p. 11 |0 PERI:(DE-600)2076603-8 |n 5 |p 11 |t Current treatment options in neurology |v 20 |y 2018 |x 1534-3138 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:132944 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)e579130c57e8c686ed1c2dedfa595985 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)567e98aaf50a1f3be9ef2f365dda213d |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)e681100c540b628a2bdbd48772b4fb50 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)0f9fbf5fd70dad2bba0760cee65c9613 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-317 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Translational cancer research |x 0 |
| 914 | 1 | _ | |y 2018 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CURR TREAT OPTION NE : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-He78)G160-20160331 |k G160 |l Neuroimmunologie und Hirntumorimmunologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)L101-20160331 |k L101 |l DKTK Heidelberg |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)G808-20160331 |k G808 |l G808 IMT IM Platform |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)G370-20160331 |k G370 |l KKE Neuroonkologie |x 3 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)G160-20160331 |
| 980 | _ | _ | |a I:(DE-He78)L101-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G808-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G370-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|